BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33490937)

  • 1. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database.
    Greco SH; August DA; Shah MM; Chen C; Moore DF; Masanam M; Turner AL; Jabbour SK; Javidian P; Grandhi MS; Kennedy TJ; Alexander HR; Carpizo DR; Langan RC
    Surg Open Sci; 2021 Jan; 3():22-28. PubMed ID: 33490937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.
    Torgeson A; Garrido-Laguna I; Tao R; Cannon GM; Scaife CL; Lloyd S
    ESMO Open; 2018; 3(1):e000282. PubMed ID: 29387477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
    Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
    J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal adenocarcinoma.
    Katou S; Wenning AS; Aeschbacher P; Morgul H; Becker F; Pascher A; Gloor B; Strücker B; Andreou A
    Surgery; 2023 Jul; 174(1):91-99. PubMed ID: 37121858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
    Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
    Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma.
    Rykina-Tameeva N; Nahm CB; Mehta S; Gill AJ; Samra JS; Mittal A
    HPB (Oxford); 2020 Nov; 22(11):1631-1636. PubMed ID: 32247587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
    Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy.
    Carpenter EL; Van Decar SG; McCarthy PM; Valdera FA; Adams AM; O'Shea AE; Smolinsky T; Thomas K; Clifton GT; Newhook TE; Peoples GE; Nelson DW; Vreeland TJ
    J Surg Oncol; 2024 May; ():. PubMed ID: 38801055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy affects margins and margins affect all: perioperative and survival outcomes in resected pancreatic adenocarcinoma.
    de Geus SWL; Kasumova GG; Sachs TE; Ng SC; Kent TS; Moser AJ; Vahrmeijer AL; Callery MP; Tseng JF
    HPB (Oxford); 2018 Jun; 20(6):573-581. PubMed ID: 29426635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy Versus Surgery First Approach.
    Hyman DW; Almerey T; Mujkanovic A; Hammons I; Tice M; Stauffer JA
    Am Surg; 2022 Aug; 88(8):1868-1874. PubMed ID: 35465681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and Survival Among Octogenarians with Localized Pancreatic Head Cancer: a National Cancer Database Analysis.
    Hue JJ; Bingmer K; Sugumar K; Ocuin LM; Rothermel LD; Winter JM; Ammori JB; Hardacre JM
    J Gastrointest Surg; 2021 Oct; 25(10):2582-2592. PubMed ID: 33634421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.